MHC Class I Deficiency care technology platforms are the digital infrastructure underpinning modern management of MHC Class I Deficiency — also known as Bare Lymphocyte Syndrome type 1 (BLS1), a rare autosomal recessive immunodeficiency caused by mutations in genes essential for MHC class I molecule assembly and surface expression (TAP1, TAP2, and Tapasin/TAPBP, encoding the Transporter associated with Antigen Processing subunits 1 and 2 and the tapasin chaperone that loads peptides onto MHC class I molecules in the endoplasmic reticulum), resulting in absent or severely reduced surface expression of HLA-A, HLA-B, and HLA-C molecules, profound CD8+ cytotoxic T-cell lymphopenia from failed thymic positive selection of MHC class I-restricted CD8+ T cells, recurrent necrotizing granulomatous lung disease with progressive bronchiectasis and obstructive pulmonary disease, and a milder immunodeficiency phenotype compared to MHC Class II Deficiency that nonetheless causes significant morbidity through recurrent upper and lower respiratory tract infections and progressive pulmonary damage — integrating CD8+ T-cell count monitoring dashboards, pulmonary function surveillance platforms, respiratory infection tracking systems, bronchiectasis progression monitoring platforms, hematopoietic stem cell transplantation evaluation and coordination dashboards, pulmonary rehabilitation coordination platforms, and patient-reported respiratory symptom diaries that enable immunologists, pulmonologists, and transplant teams to detect CD8+ T-cell depletion progression, respiratory infection recurrence, pulmonary function deterioration, bronchiectasis advancement, and HSCT candidacy changes before they produce irreversible pulmonary damage. When an MHC Class I Deficiency care platform is unavailable or degraded, immunologists cannot access the CD8+ T-cell count trajectories, pulmonary function test trends, respiratory infection recurrence data, bronchiectasis imaging progression, and HSCT evaluation data that guide treatment decisions across the overlapping MHC class I antigen presentation deficiency, CD8+ T-cell lymphopenia, chronic granulomatous pulmonary disease, and respiratory management complexity of MHC Class I Deficiency care, treatment coordination fails, and the longitudinal clinical monitoring that distinguishes stable MHC Class I Deficiency from CD8+ T-cell depletion progression, accelerating pulmonary function decline, and worsening bronchiectasis collapses. MHC Class I Deficiency — caused by mutations in TAP1, TAP2, or Tapasin encoding components of the peptide loading complex essential for MHC class I molecule surface expression: TAP1 and TAP2 form the heterodimeric ATP-binding cassette transporter that pumps proteasomal peptide fragments from the cytosol into the endoplasmic reticulum lumen, and tapasin bridges TAP with MHC class I-beta2 microglobulin complexes to facilitate peptide loading and MHC class I stabilization before surface export — produces an immunodeficiency through absent MHC class I surface expression: in the thymus, CD8+ T-cell positive selection requires recognition of self-peptides presented by MHC class I molecules on thymic cortical epithelial cells, and without MHC class I surface expression, CD8+ cytotoxic T cells fail to receive positive selection signals and undergo apoptosis, resulting in profound peripheral CD8+ T-cell lymphopenia with preserved CD4+ T-cell counts and normal NK cell counts or NK cell expansion; the NK cell expansion in some MHC Class I Deficiency patients reflects the missing-self signal that normally suppresses NK cell activation, as NK cells interpret absent HLA class I as a target signal; MHC Class I Deficiency presents with a distinctive clinical picture of recurrent sinopulmonary infections beginning in childhood, progressive necrotizing granulomatous lung disease, and bronchiectasis that causes obstructive pulmonary disease and respiratory failure in severely affected patients; unlike MHC Class II Deficiency, opportunistic infections such as Pneumocystis jirovecii pneumonia and cytomegalovirus end-organ disease are uncommon, reflecting the relatively preserved CD4+ T-cell immunity; available treatments include supportive respiratory management with aggressive infection treatment, pulmonary rehabilitation, and — in selected patients with progressive pulmonary disease — hematopoietic stem cell transplantation, though HSCT outcomes are variable and transplant indication in MHC Class I Deficiency remains under investigation; monitoring platforms track CD8+ T-cell counts, pulmonary function tests, respiratory infection recurrence frequency and severity, bronchiectasis progression, HSCT candidacy assessment, and developmental monitoring data critical to detecting pulmonary disease progression before it results in irreversible obstructive pulmonary damage or respiratory failure. The platforms that track CD8+ T-cell counts, pulmonary function trajectories, respiratory infection recurrence, bronchiectasis imaging progression, and HSCT evaluation status must remain continuously available — because missed pulmonary function decline alerts, delayed respiratory infection pattern recognition, bronchiectasis progression monitoring failures, and HSCT candidacy assessment delays lead to preventable pulmonary function deterioration, respiratory failure, and the progressive obstructive lung disease that defines preventable morbidity in inadequately monitored MHC Class I Deficiency patients.
This guide covers what MHC Class I Deficiency care technology platforms need to monitor, why continuous availability matters across the spectrum of MHC class I antigen presentation deficiency and its distinctive pulmonary and immunological manifestations, and how to build a monitoring strategy that protects CD8+ T-cell count surveillance, pulmonary function monitoring, respiratory infection tracking, bronchiectasis progression assessment, and the combined immunodeficiency and pulmonary disease management workflows that MHC Class I Deficiency care requires.
Why MHC Class I Deficiency Care Tech Platforms Cannot Afford Downtime
MHC Class I Deficiency management is built on four pillars: monitoring CD8+ T-cell counts to document the degree of CD8+ lymphopenia from failed MHC class I-restricted positive selection and to track NK cell counts that may expand compensatorily; tracking pulmonary function trajectories and respiratory infection recurrence to detect the progressive necrotizing granulomatous lung disease and bronchiectasis that is the primary driver of morbidity in MHC Class I Deficiency; assessing HSCT candidacy in patients with progressive pulmonary disease refractory to maximal medical management, with HSCT remaining under investigation as an intervention that may stabilize pulmonary progression by restoring CD8+ T-cell-mediated clearance of respiratory pathogens; and managing long-term pulmonary disease with aggressive bronchiectasis management, airway clearance, antibiotic prophylaxis, and pulmonary rehabilitation that preserves lung function and delays respiratory failure. The platforms that support MHC Class I Deficiency programs must remain continuously available — because an unmonitored patient whose FEV1 trajectory shows accelerating decline during a pulmonary function surveillance failure, or whose respiratory infection recurrence frequency is increasing without antibiotic prophylaxis escalation during an infection tracking platform outage, represents a preventable deterioration that timely digital monitoring could have averted through treatment intensification or expedited HSCT candidacy re-evaluation.
CD8+ T-cell and NK cell count monitoring defines the diagnostic immunophenotype and guides surveillance intensity. The hallmark immunophenotype of MHC Class I Deficiency — absent or severely reduced CD8+ T cells with preserved CD4+ T-cell counts and potentially expanded NK cells — distinguishes BLS1 from other immunodeficiencies and determines susceptibility to CD8+ cytotoxic T-cell-cleared pathogens; serial CD8+ T-cell count monitoring tracks the degree of CD8+ lymphopenia, identifies partial forms with residual CD8+ T cells in hypomorphic TAP or tapasin mutations, and assesses CD8+ T-cell reconstitution following HSCT; NK cell count monitoring and functional assessment characterizes compensatory NK expansion and its contribution to viral clearance in the absence of CD8+ cytotoxic T cells. Digital monitoring platforms that integrate serial flow cytometry results, track CD8+ T-cell and NK cell count trajectories, and correlate immunophenotype data with clinical respiratory infection severity provide the immune surveillance infrastructure that pulmonary disease management and HSCT candidacy decisions require.
Pulmonary function surveillance is the primary disease severity monitoring target. MHC Class I Deficiency causes progressive obstructive pulmonary disease through recurrent bacterial and viral respiratory infections that trigger necrotizing granulomatous inflammation in the lung parenchyma, producing bronchiectasis, airway obstruction, and progressive FEV1 decline; serial spirometry tracking FEV1, FVC, and FEV1/FVC ratio defines the rate of pulmonary function decline, identifies patients with accelerating deterioration requiring treatment intensification, and guides HSCT candidacy assessment; diffusing capacity (DLCO) measurement assesses the parenchymal component of pulmonary disease; exercise tolerance testing quantifies functional impairment and guides pulmonary rehabilitation intensity. Digital platforms that integrate serial pulmonary function test results, generate FEV1 decline threshold alerts, track FEV1 decline trajectory to distinguish stable from progressive pulmonary disease, and correlate pulmonary function trends with respiratory infection frequency provide the pulmonary surveillance infrastructure that prevents missed progressive pulmonary disease and delayed treatment intensification.
Bronchiectasis progression monitoring requires longitudinal imaging surveillance. Bronchiectasis is a structural pulmonary complication of recurrent respiratory infections in MHC Class I Deficiency that, once established, is irreversible and progressive without adequate infection control; serial high-resolution computed tomography (HRCT) of the chest documents the extent and progression of bronchiectasis, identifies new areas of active inflammatory change, detects granulomatous nodules, and guides antibiotic therapy and pulmonary rehabilitation intensity; HRCT bronchiectasis extent scoring provides a quantitative measure of structural pulmonary damage that can be tracked longitudinally and correlated with pulmonary function trajectories and infection recurrence frequency. Digital platforms that schedule serial HRCT assessments, integrate bronchiectasis extent scoring results, generate progression alerts when new bronchiectasis segments are identified, and correlate imaging findings with pulmonary function and infection recurrence data provide the structural pulmonary monitoring infrastructure that tracks irreversible lung damage accumulation.
Respiratory infection pattern recognition enables prophylaxis optimization and HSCT candidacy reassessment. Recurrent upper and lower respiratory tract infections — caused by bacteria (Streptococcus pneumoniae, Haemophilus influenzae, Pseudomonas aeruginosa in established bronchiectasis), respiratory viruses (respiratory syncytial virus, parainfluenza, influenza), and to some extent Mycobacteria species — drive the pulmonary function decline and bronchiectasis progression in MHC Class I Deficiency; serial tracking of respiratory infection frequency, severity, causative organisms, and antibiotic requirement defines the infection burden and guides antibiotic prophylaxis decisions, vaccination strategies, and HSCT urgency; identification of Pseudomonas aeruginosa colonization in established bronchiectasis signals advanced structural lung disease requiring aggressive suppressive antibiotic therapy. Digital platforms that integrate respiratory infection recurrence data, track antibiotic courses and organisms, generate threshold alerts when infection frequency exceeds defined thresholds, and correlate infection burden with pulmonary function and bronchiectasis progression provide the infection pattern surveillance infrastructure that prophylaxis optimization and HSCT candidacy decisions require.
What to Monitor on an MHC Class I Deficiency Care Tech Platform
CD8+ T-Cell and NK Cell Count Monitoring Platform
The CD8+ T-cell and NK cell surveillance service — integrating serial flow cytometry CD3+, CD4+, and CD8+ T-cell count result feeds, NK cell count and expansion monitoring, CD8+ T-cell count threshold alert generation, NK cell functional cytotoxicity assay result integration, T-cell reconstitution trajectory monitoring with HSCT status, and immunophenotype correlation with clinical respiratory disease severity — is the highest-priority immune monitoring target. Check at a 1-minute interval with immediate escalation. CD8+ T-cell count monitoring defines the hallmark immunophenotype of MHC Class I Deficiency and documents the degree of CD8+ cytotoxic T-cell lymphopenia that impairs viral and intracellular pathogen clearance in the respiratory tract; NK cell expansion monitoring characterizes compensatory cytotoxic immunity; platform failures that prevent access to T-cell subset data create immune status blind spots that impair respiratory disease severity correlation and HSCT candidacy assessment.
Pulmonary Function Test Surveillance Platform
Monitor the pulmonary function surveillance service — including serial spirometry FEV1, FVC, and FEV1/FVC result feeds, FEV1 decline rate calculation and trajectory alert generation, FEV1 decline threshold alert generation (>10% per year), diffusing capacity (DLCO) result integration, exercise tolerance test result feeds, pulmonary function test scheduling coordination, and HSCT candidacy trigger alert generation when FEV1 falls below defined thresholds — at a 1-minute interval. Pulmonary function monitoring is the primary disease severity surveillance target in MHC Class I Deficiency; progressive FEV1 decline defines the obstructive pulmonary disease trajectory that determines HSCT candidacy and treatment intensity; platform failures that prevent access to serial spirometry data create pulmonary disease progression blind spots that allow accelerating pulmonary function decline to go undetected until irreversible severe obstruction has accumulated.
Bronchiectasis Imaging Progression Monitoring Dashboard
Monitor the bronchiectasis imaging surveillance service — including HRCT chest scan scheduling coordination, bronchiectasis extent scoring result integration, new bronchiectasis segment detection alert generation, granulomatous nodule surveillance tracking, active inflammatory change detection alert generation, longitudinal HRCT bronchiectasis progression visualization, and imaging-pulmonary function correlation analysis — at a 1-minute interval. Bronchiectasis progression monitoring defines the structural pulmonary damage trajectory in MHC Class I Deficiency; HRCT bronchiectasis extent scoring provides a quantitative measure of irreversible lung damage accumulation that guides treatment intensity and HSCT candidacy assessment; imaging surveillance platform failures prevent the progressive structural damage detection that informs antibiotic prophylaxis escalation and HSCT timing decisions.
Respiratory Infection Tracking and Antibiotic Management Platform
Monitor the respiratory infection surveillance service — including respiratory infection episode tracking (date, severity, antibiotic requirement, organism identification), sputum culture result integration, respiratory virus PCR panel result feeds, Pseudomonas aeruginosa colonization detection alert generation, infection frequency threshold alert generation, antibiotic prophylaxis adherence monitoring, suppressive antibiotic therapy coordination, and infection burden-pulmonary function correlation analysis — at a 1-minute interval. Respiratory infection pattern monitoring defines the infection burden that drives pulmonary function decline and bronchiectasis progression in MHC Class I Deficiency; Pseudomonas aeruginosa colonization detection enables prompt suppressive therapy initiation; infection frequency threshold alerts trigger antibiotic prophylaxis escalation review; platform failures that prevent respiratory infection pattern tracking create infection burden blind spots that allow unrecognized high-frequency infection to drive preventable pulmonary function decline.
HSCT Candidacy Evaluation and Transplant Coordination Platform
Monitor the HSCT candidacy evaluation platform — including pulmonary function threshold tracking for HSCT candidacy assessment triggers, multidisciplinary HSCT candidacy review scheduling coordination, HLA typing result management when HSCT is under consideration, donor search status tracking, pre-HSCT pulmonary optimization assessment, conditioning regimen protocol coordination, post-HSCT CD8+ T-cell reconstitution tracking, and post-HSCT pulmonary function trend monitoring — at a 1-minute interval. HSCT candidacy in MHC Class I Deficiency is determined by progressive pulmonary disease refractory to maximal medical management; HSCT candidacy evaluation platform failures prevent the timely multidisciplinary review that determines whether HSCT should be pursued before severe irreversible pulmonary function impairment forecloses successful transplantation; post-HSCT CD8+ T-cell reconstitution tracking assesses immune reconstitution effectiveness and correlates with pulmonary infection frequency reduction.
Pulmonary Rehabilitation and Airway Clearance Coordination Platform
Monitor the pulmonary rehabilitation coordination service — including airway clearance therapy (oscillating positive expiratory pressure devices, chest physiotherapy) scheduling and adherence monitoring, pulmonary rehabilitation session coordination, exercise prescription tracking, respiratory therapist consultation scheduling, inhaled bronchodilator and corticosteroid prescription management, airway clearance technique instruction scheduling, and pulmonary rehabilitation response assessment — at a 2-minute interval. Pulmonary rehabilitation and airway clearance therapy are essential components of bronchiectasis management in MHC Class I Deficiency; adequate airway clearance reduces mucus plugging and bacterial stasis in bronchiectatic airways, reducing infection frequency and slowing progressive airway damage; platform failures that disrupt airway clearance scheduling and adherence monitoring allow bronchiectasis management to deteriorate without the regular coordination that sustains adequate airway clearance technique and rehabilitation intensity.
Vaccination and Infection Prevention Management Platform
Monitor the vaccination management and infection prevention platform — including pneumococcal and influenza vaccination scheduling and documentation, Haemophilus influenzae type b vaccination status tracking, vaccination response antibody titer monitoring, infection exposure alert management (meningococcal, varicella, influenza), isolation and prophylaxis coordination for immunocompromised contacts, and vaccination schedule adherence monitoring — at a 2-minute interval. Vaccination provides partial protection against bacterial pathogens that cause recurrent respiratory infections in MHC Class I Deficiency; vaccination response monitoring assesses the degree to which preserved CD4+ T-cell-dependent humoral immunity provides protective antibody responses despite absent CD8+ T cells; vaccination and infection prevention platform failures disrupt the vaccination scheduling and contact exposure management that reduces preventable respiratory infection episodes.
Telemedicine and MHC Class I Deficiency Coordinator Platform
Monitor the telemedicine session API, primary immunodeficiency program nurse coordinator messaging, pulmonology consultation scheduling, pulmonary rehabilitation coordination, and remote spirometry result transmission infrastructure at a 2-minute interval. MHC Class I Deficiency management requires continuous coordination across immunology, pulmonology, infectious disease, pulmonary rehabilitation, transplant medicine, and radiology; platform failures interrupt the multidisciplinary consultation that manages the overlapping CD8+ T-cell lymphopenia, chronic respiratory infection management, bronchiectasis care, and HSCT candidacy evaluation domains.
EHR Integration Endpoint
Monitor the EHR synchronization service at a 5-minute interval. MHC Class I Deficiency patients presenting with acute respiratory symptoms, exacerbation of bronchiectasis, or systemic infection signs require rapid provider access to their current CD8+ T-cell counts, recent pulmonary function test results, last HRCT bronchiectasis extent scoring, respiratory infection history, sputum culture organisms, antibiotic prophylaxis regimen, HSCT evaluation status, and vaccination records.
Authentication Service
Monitor authentication at a 1-minute interval. Auth failures lock immunologists, pulmonologists, and MHC Class I Deficiency care coordinators out of T-cell monitoring platforms, pulmonary function surveillance dashboards, bronchiectasis imaging tracking systems, and HSCT candidacy evaluation platforms simultaneously — disabling the entire MHC Class I Deficiency digital management infrastructure.
SSL Certificates Across All Platform Domains
Monitor certificate expiry 30 days in advance across all patient-facing, clinician-facing, and integration domains.
Alerting Strategy for MHC Class I Deficiency Care Tech Platforms
Immediate clinical escalation (24/7): CD8+ T-cell and NK cell count monitoring, pulmonary function test surveillance, bronchiectasis imaging progression monitoring, respiratory infection tracking and antibiotic management, HSCT candidacy evaluation and transplant coordination, authentication service. These affect real-time immune status assessment, pulmonary disease progression detection, infection pattern surveillance, and HSCT candidacy tracking that cannot tolerate delayed detection.
Immediate clinical operations escalation: Pulmonary rehabilitation and airway clearance coordination. Failures here affect the bronchiectasis management and airway clearance therapy scheduling that prevents accelerated mucus plugging and infection in established bronchiectasis.
High-priority immediate escalation: Vaccination and infection prevention management, telemedicine and MHC Class I Deficiency coordinator platform. Access failures interrupt infection prevention coordination and the multidisciplinary consultation that MHC Class I Deficiency's overlapping CD8+ lymphopenia, chronic respiratory disease, bronchiectasis management, and HSCT candidacy evaluation requires.
Business-hours engineering escalation: EHR synchronization. Investigate within one business hour.
Advance warning: SSL certificate expiry, 30 days in advance, across all patient-facing and integration domains.
Pulmonary function surveillance and respiratory infection tracking require 24/7 alerting because MHC Class I Deficiency is an immunodeficiency with progressive bronchiectatic lung disease in which respiratory exacerbations and pulmonary function deterioration can occur regardless of time of day — nighttime platform failures that prevent FEV1 decline trajectory alerts or block respiratory infection pattern tracking create pulmonary disease progression blind spots that delay antibiotic prophylaxis escalation and HSCT candidacy reassessment decisions.
Status Page as a Clinical Safety Signal
Primary immunodeficiency program nurses and pulmonology coordinators managing after-hours contacts from MHC Class I Deficiency families reporting acute respiratory symptoms, increased sputum production, hemoptysis, or new systemic infection signs need immediate platform status awareness before initiating escalation protocols. A published status page allows on-call coordinators to distinguish a platform incident from patient connectivity problems — and to initiate phone-based triage and emergency routing immediately when the digital platform is confirmed unavailable.
For MHC Class I Deficiency programs coordinating CD8+ T-cell monitoring, pulmonary function surveillance, bronchiectasis imaging tracking, respiratory infection management, and HSCT candidacy evaluation across geographically dispersed patients — many of whom receive care at specialized primary immunodeficiency and pulmonary rare disease centers managing both the immunodeficiency and the chronic pulmonary disease domains of MHC Class I Deficiency — a status page enables rapid identification of platform failures and activation of manual monitoring protocols. Publish the status page URL in care coordinator workstations, on-call immunology and pulmonology systems, pulmonary rehabilitation program scheduling dashboards, and radiology and transplant medicine program coordinators managing MHC Class I Deficiency pulmonary complications.
The Business Case: Pulmonary Function Preservation, HSCT Optimization, and MHC Class I Deficiency Program Quality
MHC Class I Deficiency specialty programs face significant cost exposure from preventable pulmonary function decline in inadequately monitored bronchiectasis patients, missed opportunities for HSCT candidacy evaluation before severe irreversible pulmonary function impairment forecloses successful transplantation, Pseudomonas aeruginosa colonization detected only after bronchiectasis has advanced beyond the stage where aggressive suppressive therapy could preserve remaining pulmonary function, and the progressive respiratory failure that occurs when accelerating FEV1 decline goes undetected during pulmonary function surveillance platform outages that allow months of unchecked pulmonary deterioration before the next scheduled clinic visit. Successful HSCT engraftment with CD8+ T-cell reconstitution that reduces respiratory infection frequency and halts bronchiectasis progression, and preserved pulmonary function at HSCT through aggressive bronchiectasis management and continuous pulmonary surveillance, represent the highest-value interventions in MHC Class I Deficiency management. Platform reliability that supports continuous CD8+ T-cell surveillance, pulmonary function monitoring, bronchiectasis imaging tracking, respiratory infection pattern analysis, and HSCT candidacy assessment is upstream of the most catastrophic outcomes in MHC class I antigen presentation deficiency pulmonary disease.
Missed FEV1 decline threshold alerts that delay HSCT candidacy reassessment and missed infection frequency threshold alerts that delay antibiotic prophylaxis escalation represent preventable pulmonary function deterioration episodes that allow accelerating bronchiectasis progression and respiratory failure to occur in patients who could have been protected by prompt digital monitoring and timely treatment intensification or HSCT referral. Platforms that accurately capture FEV1 decline trajectories, integrate HRCT bronchiectasis extent scoring with pulmonary function trends, track respiratory infection recurrence patterns, monitor antibiotic prophylaxis adherence, and coordinate HSCT candidacy evaluation enable immunologists and pulmonologists to distinguish expected MHC Class I Deficiency variation from pulmonary disease progression crisis, Pseudomonas colonization, and HSCT candidacy threshold before patients develop severe irreversible obstructive pulmonary disease.
MHC Class I Deficiency program quality metrics increasingly include annual FEV1 decline rates, HRCT bronchiectasis extent progression rates, proportion of patients with Pseudomonas aeruginosa colonization detected at early versus late bronchiectasis stages, time from progressive pulmonary disease recognition to HSCT candidacy evaluation, and posttransplant CD8+ T-cell reconstitution rates. Platform reliability is a direct input to outcome quality — programs whose monitoring platforms frequently fail will show higher annual FEV1 decline rates, greater bronchiectasis extent at HSCT referral, higher rates of late Pseudomonas colonization detection, and longer time-to-HSCT-candidacy-evaluation in MHC Class I Deficiency patients who needed continuous pulmonary function surveillance, respiratory infection tracking, and HSCT candidacy monitoring.
External monitoring from Vigilmon provides the documented, independent availability record that MHC Class I Deficiency program directors can present to hospital administration and payer medical directors as evidence that the program's digital infrastructure supports the level of continuous CD8+ T-cell surveillance, pulmonary function monitoring, bronchiectasis tracking, and HSCT candidacy coordination that MHC class I antigen presentation deficiency pulmonary disease care requires.
Vigilmon Setup for MHC Class I Deficiency Care Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | CD8+ T-cell and NK cell count monitoring platform | 1 min | PagerDuty (immediate, 24/7) | | Pulmonary function test surveillance platform | 1 min | PagerDuty (immediate, 24/7) | | Bronchiectasis imaging progression monitoring dashboard | 1 min | PagerDuty (immediate, 24/7) | | Respiratory infection tracking and antibiotic management | 1 min | PagerDuty (immediate, 24/7) | | HSCT candidacy evaluation and transplant coordination | 1 min | PagerDuty (immediate, 24/7) | | Auth service | 1 min | PagerDuty (immediate) | | Pulmonary rehabilitation and airway clearance coordination | 2 min | PagerDuty (immediate) | | Vaccination and infection prevention management | 2 min | PagerDuty + Slack (immediate) | | Telemedicine and MHC Class I Deficiency coordinator platform | 2 min | PagerDuty + Slack (immediate) | | EHR synchronization endpoint | 5 min | Slack (business hours) | | SSL: all platform domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add the CD8+ T-cell and NK cell count monitoring platform at a 1-minute interval with 24/7 PagerDuty alerting
- Add pulmonary function test surveillance and bronchiectasis imaging monitoring at a 1-minute interval with immediate 24/7 escalation
- Add respiratory infection tracking and antibiotic management at a 1-minute interval with immediate alerting
- Add HSCT candidacy evaluation and transplant coordination at a 1-minute interval with immediate alerting
- Add pulmonary rehabilitation and airway clearance monitoring at a 2-minute interval with immediate alerting
- Add vaccination management and telemedicine platform monitoring with immediate alerting
- Add authentication and EHR synchronization
- Enable SSL monitoring across all patient-facing and integration domains
- Publish the automatic status page URL in care coordinator workstations, on-call immunology and pulmonology systems, pulmonary rehabilitation scheduling dashboards, and transplant medicine program coordinators
Conclusion
MHC Class I Deficiency care tech platforms hold the clinical surveillance infrastructure that makes MHC class I antigen presentation deficiency pulmonary disease management survivable — CD8+ T-cell count monitoring systems, pulmonary function test surveillance platforms, bronchiectasis imaging progression tracking dashboards, respiratory infection recurrence monitoring tools, HSCT candidacy evaluation coordination systems, pulmonary rehabilitation coordination platforms, antibiotic prophylaxis adherence monitoring tools, and vaccination management systems that cannot undo the progressive obstructive pulmonary disease, irreversible bronchiectasis extent, Pseudomonas aeruginosa colonization, and the respiratory failure accumulated during periods of unmonitored FEV1 decline, absent bronchiectasis imaging surveillance, and unrecognized escalating respiratory infection frequency. Their availability is a prerequisite for CD8+ T-cell count surveillance, pulmonary function trajectory monitoring, bronchiectasis structural progression detection, respiratory infection pattern recognition, HSCT candidacy evaluation, and the specialist access that patients with MHC Class I Deficiency depend on throughout an illness that requires continuous CD8+ T-cell monitoring, annual spirometry with FEV1 decline trajectory analysis, regular HRCT bronchiectasis extent scoring, respiratory infection burden tracking, antibiotic prophylaxis optimization, HSCT candidacy assessment, and pulmonary rehabilitation coordination to preserve lung function and detect the clinical signals — FEV1 accelerating decline, HRCT bronchiectasis extent progression, new Pseudomonas aeruginosa isolation, respiratory infection frequency threshold breach, exercise tolerance deterioration, HSCT candidacy threshold crossing — that define MHC Class I Deficiency pulmonary deterioration before it progresses to the severe irreversible obstructive pulmonary disease, Pseudomonas colonization of established bronchiectasis, and the respiratory failure that define preventable morbidity in inadequately monitored patients with Bare Lymphocyte Syndrome type 1. When CD8+ T-cell surveillance platforms go offline, pulmonary function monitoring fails, or bronchiectasis imaging tracking systems are unavailable, the clinical consequences extend to a disease where the difference between adequate and inadequate monitoring is measured in the annual FEV1 units lost during unmonitored intervals between scheduled spirometry visits, the HRCT bronchiectasis extent segments that accumulate from unrecognized high-frequency respiratory infections that exceeded the prophylaxis escalation threshold but were never counted, and the patients who cross the HSCT candidacy threshold during a monitoring platform outage and are not referred until their next scheduled clinic visit — by which time irreversible pulmonary function impairment has foreclosed optimal transplant timing.
External monitoring from Vigilmon provides the independent, outside-in availability view that MHC Class I Deficiency program directors and health system IT teams need to catch failures before they affect pulmonary function surveillance or respiratory infection tracking — with the documented incident record that accreditation bodies and payer audit teams accept as evidence of operational maturity.
Start monitoring your MHC Class I Deficiency care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and PagerDuty integration. No agent required. No credit card.
Tags: #monitoring #MHCclassIdeficiency #BareLymphocyteSyndrome #BLS1 #CD8lymphopenia #bronchiectasis #TAP1 #TAP2 #tapasin #primaryimmunodeficiency #HSCT #pulmonaryimmunodeficiency #antigenPresentation #HLA-ABC #lymphocytereconstitution #granulomatouslung #immunodeficiency #immunology #pulmonology #transplantmedicine #healthtech #uptime #clinicaldocumentation #sre